Peculiarities of Anamnesis and Life Quality in Patients with Atrial Fibrillation
Atrial fibrillation is a common rhythm disturbance. One of the main parameters being crucial for the choice of tactics of treatment and prevention of complications is the life quality of patients.
The objective of our study was to evaluate this indicator in patients with atrial fibrillation depending on different approaches to treatment. The study involved 254 patients with paroxysmal and persistent forms of atrial fibrillation and 42 practically healthy persons. The main features of anamnesis, presence of comorbidities, aggravating risk factors were studied as well as a survey using “AFEQT Questionnaire” was conducted. When studying the anamnesis it was revealed that patients treated by medications only (the first experimental group) had arterial hypertension as a main presumable cause of atrial fibrillation (92.4%); in one third of cases different forms of coronary artery disease and heart failure were diagnosed (38.6% and 33.3%, respectively). In the fourth group (after left ventricular revascularization) a prevailing cause of atrial fibrillation was coronary heart disease (100%). In the second group (after cardioversion) as well as in the third group (after ablation) the largest proportion of patients was also diagnosed with arterial hypertension – 62.0% and 40.9%, respectively. The mean total AFEQT score among the control group was 82.3±3.1 points. Patients of the first group scored the minimum value among interviewed patients -53.4±4.6 - that was significantly less compared to the control group, р<0.05. The total average value of the third group was significantly higher than that in the first group, 69.3±4.6 points against 53.4±4.6 points, respectively, р<0.05.
Thus, it was found that the lowest life quality is typical for patients treated with medications only. The patients after ablation have the highest life quality. Left ventricle revascularization slightly improves life quality, but this trend is not statistically significant.
Lévy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the Alfa Study. Circulation. 1999;99:3028-3035.
Spertus J, Dorian P, Bubien R, et al. Development and validation of the Atrial Fibrillation Effect on Quality of Life (AFEQT) Questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2011;4(1):15-25. doi: 10.1161/CIRCEP.110.958033
Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol. 2004;43(2):241-247.
Engelmann M, Godtfredsen J. Assessment of quality of life in pharmacological treatment of atrial fibrillation. Heart Drug 2003;3:14-24 doi:10.1159/000070904
Engelmann MD, Pehrson S. Quality of life in nonpharmacologic treatment of atrial fibrillation. Eur Heart J. 2003;24(15):1387-1400.
Kannel WB, Abbot RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982;306(17):1018-1022.
Calkins H, Brugada J, Packer D, et al. HRS/EHRA/ECAS Expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. Heart Rhythm. 2007;40:816-861.
Lüderitz B, Jung W. Quality of Life in Patients with atrial fibrillation. Arch Intern Med. 2000;160(12):1749-1757.
Cooper HA, Bloomfield DA, Bush DE, et al. Relation between achieved Heart rate and outcomes in patients with atrial fibrillation (AFFIRM study). Am J Cardiol. 2004;93(10):1247-1253.
Reynolds M, Ellis E, Zimetbaum P. Quality of life in atrial fibrillation: measurement tools and impact of interventions. J Cardiovasc Electrophysiol. 2008; 19(7):762–768. doi: 10.1111/j.1540-8167.2007.01091.x
Miyasaka Y, Barnes M, Gersh B, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119-125.
Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol. 2000;36(4):1303-1309.
Braganca E, Luna Filho B, Maria VH, et al. Validating a new quality of life questionnaire for atrial fibrillation patients. Int J Cardiol. 2010;143(3):391-8. doi: 10.1016/j.ijcard.2009.03.087.
Arribas F, Ormaetxe JM, Peinado R, et al. Validation of the AF-QoL, a disease-specific quality of life questionnaire for patients with atrial fibrillation. Europace. 2010;12(3):364-70. doi: 10.1093/europace/eup421.
Hoiho OV. Practical use of STATISTIKA for analysis of biomedical data. Kyiv. B.v. 2004;76.
Copyright (c) 2016 Ofori Ishmael Nii, E. Ya. Warenytsia, O. M. Libryk
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).